Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey

Basit Öğe Kaydı
dc.authorscopusid8927152600
dc.authorscopusid56893368500
dc.authorscopusid56195646300
dc.authorscopusid24480152400
dc.authorscopusid51665869400
dc.authorscopusid25225546400
dc.authorscopusid37102664500
dc.contributor.authorÖnlen, Yusuf
dc.contributor.authorBal, Tayibe
dc.contributor.authorÇabalak, Mehmet
dc.contributor.authorÖztoprak, Nefise Çuvalcı
dc.contributor.authorSarı, Nagehan Didem
dc.contributor.authorKurtaran, Behice
dc.contributor.authorŞenateş, Ebubekir
dc.date.accessioned2023-07-26T11:50:59Z
dc.date.available2023-07-26T11:50:59Z
dc.date.issued2022
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. Methods: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (?65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. Results: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). Conclusion: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults. Copyright @ Author(s)en_US
dc.identifier.doi10.5152/tjg.2022.21271
dc.identifier.endpage873en_US
dc.identifier.issn1300-4948
dc.identifier.issue10en_US
dc.identifier.pmid35946896en_US
dc.identifier.scopus2-s2.0-85139571415en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage862en_US
dc.identifier.trdizinid1134402en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2022.21271
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1134402
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12470
dc.identifier.volume33en_US
dc.identifier.wosWOS:000955590200007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorİnce, Nevin
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectAgeen_US
dc.subjectchronic hepatitis Cen_US
dc.subjectdirect-acting antiviral agentsen_US
dc.subjectelderlyen_US
dc.subjectTurkeyen_US
dc.subjectantivirus agenten_US
dc.subjectdasabuvir plus ombitasvir plus paritaprevir plus ritonaviren_US
dc.subjectledipasvir plus sofosbuviren_US
dc.subjectribavirinen_US
dc.subjectsofosbuviren_US
dc.subjectantivirus agenten_US
dc.subjectribavirinen_US
dc.subjectsofosbuviren_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectanemiaen_US
dc.subjectangioneurotic edemaen_US
dc.subjectArticleen_US
dc.subjectbleedingen_US
dc.subjectchronic hepatitis Cen_US
dc.subjectcohort analysisen_US
dc.subjectconstipationen_US
dc.subjectdecompensated liver cirrhosisen_US
dc.subjectdemographyen_US
dc.subjectdrug efficacyen_US
dc.subjectdrug safetyen_US
dc.subjectdrug withdrawalen_US
dc.subjectdyspneaen_US
dc.subjectfatigueen_US
dc.subjectfemaleen_US
dc.subjectgroups by ageen_US
dc.subjectheadacheen_US
dc.subjectHepatitis C virus genotype 1en_US
dc.subjecthumanen_US
dc.subjecthyperbilirubinemiaen_US
dc.subjectinsomniaen_US
dc.subjectliver cell carcinomaen_US
dc.subjectliver cirrhosisen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmedical historyen_US
dc.subjectmiddle ageden_US
dc.subjectmulticenter studyen_US
dc.subjectnauseaen_US
dc.subjectnonhumanen_US
dc.subjectobservational studyen_US
dc.subjectpopulation researchen_US
dc.subjectprospective studyen_US
dc.subjectpruritusen_US
dc.subjectpsychosisen_US
dc.subjectsex differenceen_US
dc.subjectsustained virologic responseen_US
dc.subjectTurkey (republic)en_US
dc.subjecturticariaen_US
dc.subjectyoung adulten_US
dc.subjectchronic hepatitis Cen_US
dc.subjectclinical trialen_US
dc.subjectcombination drug therapyen_US
dc.subjectgeneticsen_US
dc.subjectHepacivirusen_US
dc.subjecttreatment outcomeen_US
dc.subjectturkey (bird)en_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAntiviral Agentsen_US
dc.subjectDrug Therapy, Combinationen_US
dc.subjectHepacivirusen_US
dc.subjectHepatitis C, Chronicen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectProspective Studiesen_US
dc.subjectRibavirinen_US
dc.subjectSofosbuviren_US
dc.subjectSustained Virologic Responseen_US
dc.subjectTreatment Outcomeen_US
dc.subjectTurkeyen_US
dc.titleEfficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12470.pdf
Boyut:
3.15 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu